Gene and Cell Therapy Safety | Enduring Framework Required - 2022 World Medical Innovation Forum

Gene and Cell Therapy Safety | Enduring Framework Required

Gene and Cell Therapy Safety | Enduring Framework Required

Wednesday, May 4, 2022

10:20 AM – 11:00 AM America Ballroom View Here

This panel will feature an in-depth discussion of the safety of gene and cell therapies. What are the unique safety concerns in this field, both acute and potential long-term risks? Which of these concerns are supported by clinical data versus the presumption of theoretical risk? What are the key issues for AAV-based gene therapies? Will redosing become feasible? What are the predominant safety concerns for in vivo versus ex vivo GCT modalities, including base editing?

Moderator:
Christine Seidman, MD
  • Director, Cardiovascular Genetics Center, BWH
  • Smith Professor of Medicine & Genetics, HMS
Panelists:
Rick Fair
  • President & CEO, Bellicum
Alexandria Forbes, PhD
  • President & CEO, MeiraGTx
Sekar Kathiresan, MD
  • CEO, Verve Therapeutics
Rick Modi
  • CEO, Affinia Therapeutics